Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

University College, London · with CHDI Foundation, Inc. · NCT02855476

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 11–75 · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
2500
US sites recruiting
5
Study start
January 1, 2017
Record last updated
April 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

Conditions: Huntington's Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age (18-75 years controls, early/late premanifest HD and incomplete penetrance HD, 21-75 years early/moderate/advanced manifest HD, ≥11 years juvenile HD)
  • Enroll HD participant
  • Capable of consenting or have a legal representative (parent/guardian for juveniles)
  • Capable of complying with study procedures
  • All participants other than family and community controls must have had a genetic test for HD

Exclusion Criteria

  • Drug trial within 30 days of any sampling visit
  • Changes in medication (antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD within 30 days)
  • Antiplatelet or anticoagulant therapy within 14 days
  • Significant comorbidity
  • Needle phobia, headache, spinal surgery / deformity
  • Clotting or bruising disorder
  • Screening blood test abnormalities >10% outside normal range
  • Drug / alcohol abuse
  • Positive urine pregnancy test at any screening or sampling visit for females of childbearing potential
  • Predictable non compliance or unwillingness
  • Serious adverse event related to HDClarity study procedures or any lumbar puncture procedure performed for any reason in the previous 30 days

Recruiting US locations

  • Cenexel

    Englewood, CO

    Site contact: Jessica Crall · 303-867-5473 · j.crall@cenexel.com

  • Georgetown University

    Washington D.C., DC 20057

    Site contact: Erin Koppel · 202-687-1525 · ek875@georgetown.edu

  • John Hopkins University

    Baltimore, MD 21287

    Site contact: Susan Robinson · 410-955-1349 · srobin95@jhmi.edu

  • Vanderbilt University Medical Center

    Nashville, TN 37212

    Site contact: Carol Wallace, RN · 615-936-1007 · carol.l.wallace@vumc.org

  • University of Texas Health Science Center

    Houston, TX 77030

    Site contact: Brittany Duncan · 713-486-3134 · brittany.j.duncan@uth.tmc.edu

Study contacts (from the official record)

  • Katarzyna Schubert, PhD · hdclarity-cc@enroll-hd.org
  • Gail Owen, PhD · +44 1273 640 688 · g.owen@ucl.ac.uk
All neurology studies in Colorado →
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative… (NCT02855476) | Bored Studies